Why ANI Pharmaceuticals Inc. Shares Soared
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of ANI Pharmaceuticals , a specialty pharmaceutical company that markets branded and generic pharmaceutical products, soared as much as 11% after filing an 8-K with the Securities and Exchange Commission this morning with its June 2014 corporate presentation attached.
So what: ANI Pharmaceuticals' corporate presentation was an update for investors on how the company has performed historically, and recently, as well as where it's headed next. As ANI points out in its presentation, which can be viewed in its entirety here, its first-quarter 2014 results saw revenue growth of 96% as well as operating income growth of 767% to $3.5 million. What seems to be really exciting investors today is its pipeline update which it notes includes "46 products in development" with six filed abbreviated new drug applications (ANDAs) and another 40 ANDAs in progress. ANI estimates that the current combined market value of these therapies is $2.7 billion. Of course, generics price much lower than branded products so keep that in mind, but its generic growth is clearly taking shape.
Now what: With such a robust generic pipeline it's no wonder that EPS estimates have been screaming higher for ANI Pharmaceuticals over the past couple of months. With a projected growth rate of better than 20% next year and a forward P/E below 17, even following today's spike higher, the insinuation from a fundamental investors' standpoint is that ANI may still be undervalued. However, just to act as a voice of reason as well, consider that generic drugs also weaken margins, so as it introduces more and more of these biosimilar drugs to market its gross margin may dip a bit. I'd hardly call this a deal-breaker for investors, but it's a figure worth monitoring.
ANI Pharmaceuticals may have soared today, but it'll likely have a tough time keeping pace with this top stock over the long run
Give us five minutes and we'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks one stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.
The article Why ANI Pharmaceuticals Inc. Shares Soared originally appeared on Fool.com.Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.